The Cancer Risk panel of genes is intended to screen the patient's genetic profile and uncover the predisposition or the risk to develop different types of cancer (including breast, ovarian, pancreas, colorectal, prostate, bladder, urinary, and endocrine). In this panel, we utilize next generation sequencing (NGS) technology for screening various cancer related genes, which have been clinically proven to increase the likelihood to develop cancer.
When several cases of cancer run in the family, there are a substantial grounds to assume that there is a genetic background for hereditary cancer. Based on the results, this test enables physicians to provide different preventive measures for their patients; the results may encourage vigilance through more frequent testing, awareness of symptoms, and lifestyle changes along with surgical interventions when required.
Identifying your risk is the first step in preventing the disease, prevent disease aggressiveness or reducing the risk of developing a second cancer. Moreover, this test can identify at-risk family members, or exclude members with decreased risk.
76 selected genes- simultaneous analysis of 76 selected genes which are researched-based with clinical relevance gives your physician clear results regarding your actual risk to develop cancer.
Confirmed results- the presence of clinically significant DNA variants (pathogenic/likely pathogenic and VUS) is confirmed by the golden standard Sanger Sequencing.
Stringent sequencing method- we utilize a stringent sequencing and analysis method on all of our risk tests which yields higher sensitivity and specificity rates.